SPECT Scans to Improve Treatment for Advanced Cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study uses special scans (SPECT imaging) to see how radium or lutetium treatments move through your body, helping doctors plan better doses. It's for people with advanced prostate cancer (getting Radium-223) or advanced neuroendocrine tumors (getting 177Lu treatments).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced prostate cancer and are planning to start treatment with Radium-223, OR you have advanced cancer (like neuroendocrine tumors) and are planning treatment with 177Lu-DOTATATE or 177Lu-PSMA-617.
- You are 18 years or older.
- You are able to be up and about at least half the day (ECOG score 0-2).
- Your cancer has been confirmed by a biopsy or tissue sample.
- You are not in another study that would conflict with this one.
- You can lie still for a SPECT scan and come back for a few follow-up scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special imaging scan (SPECT/CT) with a small amount of radioactive tracer to look at prostate cancer. It aims to see how well the scan matches your prostate cancer tests and may help improve detection and assessment.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
This study uses a special type of scan (quantitative SPECT) to measure how Radium-223 (Xofigo) works in your bones. It helps doctors better understand treatment for prostate cancer that has spread to the bones.
This study tests a new experimental treatment for advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment is a radioactive drug that targets a protein called PSMA on cancer cells, aiming to deliver radiation directly to the tumor.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.